Business
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a
About this update from Voyager Therapeutics, Inc.
[{"type":"image","alt":"Voyager Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Voyager Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/1842388f47778127775e1c1d222cee9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aA28rCi8Vnw73esVg7Kfbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1842388f47778127775e1c1d222cee9a","width":300,"height":300}},"lazy":false},{"type":"text","content":"- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study -","length":183,"tagName":"p"},{"type":"text","content":"- Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 -","length":143,"tagName":"p"},{"type":"text","content":"- Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - ","length":74,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease (AD). Data on tau silencing gene therapy VY1706 and anti-tau antibody VY7523 will be presented at the upcoming 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2025), taking place April 1-5, 2025, in Vienna. Additionally, Voyager announced it will host a live webcast recapping key AD/PD™ 2025 data at 4:30 p.m. ET on Monday, April 7, 2025.","length":722,"tagName":"p"},{"type":"text","content":"“Emerging data continue to strengthen our conviction that tau is the next critical target in Alzheimer’s disease, which supports Voyager’s advancement of both antibody and gene therapy approaches,” said Toby Ferguson, M.D., Ph.D., Chief Medical Officer of Voyager Therapeutics. “When I look across the design of these two molecules, the preclinical data each has generated, and the emerging clinical profile for our antibody, I believe our anti-tau antibody and gene the...